NeuroPace (NPCE) Cash from Operations Growth (1y) (2021 - 2026)
Powered by 
Analysis
NeuroPace (NPCE) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 21.54% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 48.31% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 64.80% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 13.50% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 14.62% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 124.64% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 0.99% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | -11.16% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -12.60% |
| 10 | NeuroPace | 493.15 Mn | 441.45 Mn | 18.91 Mn | -85.86% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -85.86% |
| Mar 31, 2026 | 21.33% |
| Dec 31, 2025 | 110.65% |
| Sep 30, 2025 | -7.90% |
| Jun 30, 2025 | 46.15% |
| Mar 31, 2025 | 0.37% |
| Dec 31, 2024 | -43.87% |
| Sep 30, 2024 | 22.96% |
| Jun 30, 2024 | 11.36% |
| Mar 31, 2024 | 22.39% |
| Dec 31, 2023 | 58.08% |
| Sep 30, 2023 | 66.79% |
| Jun 30, 2023 | 58.88% |
| Mar 31, 2023 | 14.91% |
| Dec 31, 2022 | 3.98% |
| Sep 30, 2022 | -57.41% |
| Jun 30, 2022 | -76.45% |
| Mar 31, 2022 | -92.05% |
| Dec 31, 2021 | -27.95% |
| Sep 30, 2021 | 18.52% |